81 related articles for article (PubMed ID: 29028755)
1. Finding Resolution for the Responsible Transparency of Economic Models in Health and Medicine.
Padula WV; McQueen RB; Pronovost PJ
Med Care; 2017 Nov; 55(11):915-917. PubMed ID: 29028755
[TBL] [Abstract][Full Text] [Related]
2. Can Economic Model Transparency Improve Provider Interpretation of Cost-effectiveness Analysis? Evaluating Tradeoffs Presented by the Second Panel on Cost-effectiveness in Health and Medicine.
Padula WV; McQueen RB; Pronovost PJ
Med Care; 2017 Nov; 55(11):909-911. PubMed ID: 29028753
[TBL] [Abstract][Full Text] [Related]
3. Can Economic Model Transparency Improve Provider Interpretation of Cost-Effectiveness Analysis? A Response.
Cohen JT; Wong JB
Med Care; 2017 Nov; 55(11):912-914. PubMed ID: 29028754
[TBL] [Abstract][Full Text] [Related]
4. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
5. Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States.
Carlson JJ; Walton SM; Basu A; Chapman RH; Campbell JD; McQueen RB; Pearson SD; Touchette DR; Veenstra D; Whittington MD; Ollendorf DA
Pharmacoeconomics; 2019 Nov; 37(11):1321-1327. PubMed ID: 31485925
[TBL] [Abstract][Full Text] [Related]
6. Characterizing the Validity and Real-World Utility of Health Technology Assessments in Healthcare: Future Directions Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modelling".
Zawadzki NK; Hay JW
Int J Health Policy Manag; 2020 Aug; 9(8):352-355. PubMed ID: 32613807
[TBL] [Abstract][Full Text] [Related]
7. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
8. Developing Open-Source Models for the US Health System: Practical Experiences and Challenges to Date with the Open-Source Value Project.
Jansen JP; Incerti D; Linthicum MT
Pharmacoeconomics; 2019 Nov; 37(11):1313-1320. PubMed ID: 31392665
[TBL] [Abstract][Full Text] [Related]
9. Reviewing the evidence to inform the population of cost-effectiveness models within health technology assessments.
Kaltenthaler E; Tappenden P; Paisley S
Value Health; 2013; 16(5):830-6. PubMed ID: 23947977
[TBL] [Abstract][Full Text] [Related]
10. A Need for Change! A Coding Framework for Improving Transparency in Decision Modeling.
Alarid-Escudero F; Krijkamp EM; Pechlivanoglou P; Jalal H; Kao SZ; Yang A; Enns EA
Pharmacoeconomics; 2019 Nov; 37(11):1329-1339. PubMed ID: 31549359
[TBL] [Abstract][Full Text] [Related]
11. Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview.
Dasbach EJ; Elbasha EH
Pharmacoeconomics; 2017 Jul; 35(7):673-683. PubMed ID: 28456972
[TBL] [Abstract][Full Text] [Related]
12. A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment.
Tarride JE; Hopkins R; Blackhouse G; Bowen JM; Bischof M; Von Keyserlingk C; O'Reilly D; Xie F; Goeree R
Pharmacoeconomics; 2010; 28(4):255-77. PubMed ID: 20222752
[TBL] [Abstract][Full Text] [Related]
13. A research roadmap for complementary and alternative medicine - what we need to know by 2020.
Fischer F; Lewith G; Witt CM; Linde K; von Ammon K; Cardini F; Falkenberg T; Fønnebø V; Johannessen H; Reiter B; Uehleke B; Weidenhammer W; Brinkhaus B
Forsch Komplementmed; 2014; 21(2):e1-16. PubMed ID: 24851850
[TBL] [Abstract][Full Text] [Related]
14. The use of health economic information by reimbursement authorities.
Drummond MF
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii60-3. PubMed ID: 14585919
[TBL] [Abstract][Full Text] [Related]
15. Through the looking glass: making the design and output of economic models useful for setting medical policy.
Ollendorf DA; Pearson SD
J Comp Eff Res; 2014 Jan; 3(1):53-61. PubMed ID: 24345257
[TBL] [Abstract][Full Text] [Related]
16. Mental health care system optimization from a health-economics perspective: where to sow and where to reap?
Lokkerbol J; Weehuizen R; Mavranezouli I; Mihalopoulos C; Smit F
J Ment Health Policy Econ; 2014 Jun; 17(2):51-60. PubMed ID: 25153093
[TBL] [Abstract][Full Text] [Related]
17. Transparency in Decision Modelling: What, Why, Who and How?
Sampson CJ; Arnold R; Bryan S; Clarke P; Ekins S; Hatswell A; Hawkins N; Langham S; Marshall D; Sadatsafavi M; Sullivan W; Wilson ECF; Wrightson T
Pharmacoeconomics; 2019 Nov; 37(11):1355-1369. PubMed ID: 31240636
[TBL] [Abstract][Full Text] [Related]
18. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
[TBL] [Abstract][Full Text] [Related]
19. Current methodological issues in the economic assessment of personalized medicine.
Annemans L; Redekop K; Payne K
Value Health; 2013; 16(6 Suppl):S20-6. PubMed ID: 24034308
[TBL] [Abstract][Full Text] [Related]
20. Experiences of Structured Elicitation for Model-Based Cost-Effectiveness Analyses.
Soares MO; Sharples L; Morton A; Claxton K; Bojke L
Value Health; 2018 Jun; 21(6):715-723. PubMed ID: 29909877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
